Clinical trials: sponsored by The Netherlands Cancer Institute
Myxoid Liposarcoma
International Prospective Registry on Local Treatment Approaches in MLS
To prospectively study commonly used local treatment approaches in Myxoid Liposarcoma (MLS)
- Trial name
- NCT04699292
- Testing
- Surgery, Preoperative RT 36Gy, Preoperative RT 50Gy
- Where
- Netherlands
- Volunteers
- 300 people
- Sponsor
- The Netherlands Cancer Institute
Breast Cancer
AssessinG Efficacy of Carboplatin and ATezOlizumab in Metastatic Lobular Breast Cancer
This is a single arm multicenter non-randomized phase II trial testing the efficacy of the combination of carboplatin plus atezolizumab in metastatic ILC
- Trial name
- GELATO (NCT03147040)
- Testing
- Carboplatin, Atezolizumab
- Where
- 4 sites in Netherlands
- Volunteers
- 23 people
- Sponsor
- The Netherlands Cancer Institute
Breast Cancer
A Feasibility Study of Niraparib for Advanced, BRCA1-like, HER2-negative Breast Cancer Patients
Patients with locally recurrent BRCA1-like, HER2-negative breast cancer that cannot be treated with curative intent by local treatment (surgery, radiotherapy +/- hyperthermia) or patients with metastatic BRCA1-like, HER2-negative…
- Trial name
- NCT02826512
- Testing
- Niraparib
- Where
- 3 sites in Netherlands
- Volunteers
- 9 people
- Sponsor
- The Netherlands Cancer Institute
Breast Cancer
The Impact of a Web-based Patient Decision Aid for Women Considering Breast Reconstruction
This study evaluates the impact of an online patient decision aid on the process of decision making regarding breast reconstruction and the decision quality in women with breast cancer undergoing mastectomy and considering…
- Trial name
- TANGO (NCT03791138)
- Testing
- online patient decision aid
- Where
- 8 sites in Netherlands
- Volunteers
- 250 people
- Sponsor
- The Netherlands Cancer Institute
Quality of Life, Late Effect
Health-related Quality of Life and Late Effects Among SURVivors of Cancer in Adolescence and Young Adulthood: The SURVAYA Study
Rationale: Adolescent and young adult (AYA) cancer survivors, diagnosed between 18-39 years, much more than children, suffer from delay in diagnosis, lack of centralization of care, age-adjusted expertise and follow-up care.
- Conditions
- Quality of Life, Late Effect, Survivorship, Lifestyle
- Trial name
- NCT05379387
- Where
- Netherlands
- Volunteers
- 4,000 people
- Sponsor
- The Netherlands Cancer Institute
Cognitive Problems
Internet-based WOrk-related Cognitive Rehabilitation for Cancer Survivors: a Randomized Controlled Trial
Many of the occupationally active cancer survivors experience cognitive problems.Both from an individual and a societal perspective, it is important to sustain cancer survivors' employability.The aim of the current study is to…
- Trial name
- i-WORC (NCT03900806)
- Testing
- online cognitive rehabilitation
- Where
- Netherlands
- Volunteers
- 261 people
- Sponsor
- The Netherlands Cancer Institute
Prostate Cancer Metastatic, Metastasis
Optimal Sequencing of Treatment Options for Poor Risk mCRPC Previously Treated With Docetaxel
Rationale: The aim of this study is to identify the optimal second line treatment option for patients with a poor prognosis metastasized Castration Resistant Prostate Cancer (mCRPC) with respect to Clinical Benefit Rate (CBR)…
- Trial name
- OSTRICh (NCT03295565)
- Testing
- Cabazitaxel, Abiraterone, Enzalutamide
- Where
- 19 sites in Netherlands
- Volunteers
- 100 people
- Sponsor
- The Netherlands Cancer Institute
Prostate Cancer Metastatic, Bone Metastases
Registry of Treatment Outcomes of Symptomatic Metastasized Castration Resistant Prostate Cancer Treated With Radium-223
Radium-223 is the 5th treatment for metastasized castration resistant prostate cancer with a proven overall survival benefit. The improved survival of Radium-223 over placebo was demonstrated in the ALSYMPCA trial, which included…
- Trial name
- ROTOR (NCT03223597)
- Testing
- Radium-223 dichloride
- Where
- 20 sites in Netherlands
- Volunteers
- 300 people
- Sponsor
- The Netherlands Cancer Institute
Stage III Skin Melanoma
Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients
This is a two-arm Phase 1b feasibility trial consisting of 20 patients receiving the combination of ipilimumab+nivolumab, either adjuvant, or split neo-adjuvant and adjuvant.
- Trial name
- OpACIN (NCT02437279)
- Testing
- Surgery of the tumor, Infusion with ipilimumab 3 mg/kg q3wks, Infusion with nivolumab 1 mg/kg q3wks
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- The Netherlands Cancer Institute
Breast Cancer
Nivolumab After Induction Treatment in Triple-negative Breast Cancer (TNBC) Patients
This is a single center non-blinded randomized non-comparative phase II trial. The first stage of the trial consists of five arms ( with induction treatment followed by nivolumab, 1 with no induction treatment before nivolumab).
- Trial name
- TONIC (NCT02499367)
- Testing
- Nivolumab, Radiation therapy, Low dose doxorubicin
- Where
- Netherlands
- Volunteers
- 84 people
- Sponsor
- The Netherlands Cancer Institute
Metastatic Breast Cancer
Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients
This is a single center non-blinded randomized multi-cohort non-comparative phase II trial with a Simon's two-stage design.
- Trial name
- TONIC-2 (NCT04159818)
- Testing
- Nivolumab, Cisplatin, Low dose doxorubicin
- Where
- Netherlands
- Volunteers
- 52 people
- Sponsor
- The Netherlands Cancer Institute
Second Cancer, Survivorship
The Prospective Observational COMPRAYA Cohort Study
Rationale: Childhood cancer survivorship attracts attention globally, because successes in treatment have led to increasing number of survivors who reach adulthood, in which survivorship issues affecting health-related quality of…
- Conditions
- Second Cancer, Survivorship, Fertility Issues, Distress, Emotional
- Trial name
- COMPRAYA (NCT04682470)
- Testing
- No intervention ; observational
- Where
- Netherlands
- Volunteers
- 4,000 people
- Sponsor
- The Netherlands Cancer Institute
Colorectal Cancer
Molecular Stool Testing for Colorectal Cancer Surveillance
Rationale: Since January 2014 the Dutch screening programme for bowel cancer has been implemented. Screening will increase the demand for surveillance.
- Trial name
- MOCCAS (NCT02715141)
- Testing
- Collection of stool sample
- Where
- Netherlands
- Volunteers
- 3,966 people
- Sponsor
- The Netherlands Cancer Institute
NSCLC
Dose Escalation by Boosting Radiation Dose Within the Primary Tumor Using FDG-PET-CT Scan in Stage IB, II and III NSCLC
Increasing ("boosting") the radiation dose for patients with non-small cell lung carcinoma to the individual maximal dose which can safely be given.
- Trial name
- PET Boost (NCT01024829)
- Testing
- Radiotherapy
- Where
- 7 sites in Belgium, Denmark and 3 more
- Volunteers
- 150 people
- Sponsor
- The Netherlands Cancer Institute
Breast Cancer
Radiation Dose Intensity Study in Breast Cancer in Young Women
hypothesis: 10 Gy additional boost to the tumor bed will yield an increase in local control at 10 years from 88% to 93%, with still acceptable cosmesis.
- Trial name
- NCT00212121
- Testing
- high dose boost, boost
- Where
- 18 sites in France, Netherlands
- Volunteers
- 2,400 people
- Sponsor
- The Netherlands Cancer Institute
Small Cell Lung Cancer, Lung Cancer
Hippocampus Avoidance PCI vs PCI
Using Intensity Modulated radiotherapy it is possible to treat the entire brain to standard dosages of whole-brain radiation, while keeping the radiation dose to the hippocampus low.
- Trial name
- HA-PCI (NCT01780675)
- Testing
- Radiation Prophylactic Cranial Irradiation, Radiation Hippocampal Avoidance PCI
- Where
- 9 sites in Belgium, Netherlands
- Volunteers
- 168 people
- Sponsor
- The Netherlands Cancer Institute
Carcinoma, Non-Small Cell Lung
Cisplatin-Pemetrexed Compared With Carboplatin-Paclitaxel-Bevacizumab in KRAS Mutated Non-small Cell Lung Cancer
The purpose of this study is to determine whether carboplatin-paclitaxel-bevacizumab results in a prolonged progression free survival compared to cisplatin-pemetrexed as first line treatment in patients with KRAS mutated…
- Trial name
- NCT02743923
- Testing
- carboplatin, paclitaxel, Bevacizumab
- Where
- 28 sites in Netherlands
- Volunteers
- 203 people
- Sponsor
- The Netherlands Cancer Institute
Prostate Cancer
The Prognostic Role of Lymph Node Dissection In Men With Prostate Cancer Treated With Radical Prostatectomy
An extended pelvic lymph node dissection (ePLND) is the most accurate staging method to assess the presence of lymph node metastases in prostate cancer (PCa) patients. The therapeutic value, however remains unclear.
- Trial name
- NCT05109910
- Testing
- Pelvic lymph node dissection
- Where
- Netherlands
- Volunteers
- 284 people
- Sponsor
- The Netherlands Cancer Institute
Breast Cancer, Cervix Cancer
Carboplatin-cyclophosphamide Combined With Atezolizumab
This is a single centre, 3+3, dose finding, open label, phase 1b clinical study of carboplatin and cyclophosphamide, in combination with atezolizumab.
- Conditions
- Breast Cancer, Cervix Cancer, Ovarian Cancer, Endometrial Cancer
- Trial name
- PROLOG (NCT02914470)
- Testing
- carbplatin, cyclophophamide, atezolizumab
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- The Netherlands Cancer Institute
HNSCC
Dose-Effect Relation of Salivary Gland Irradiation
Optimization of radiotherapy to reduce xerostomia is difficult, because many gland locations cannot be seen with current imaging modalities and biological dose-effect are currently insufficiently understood.
- Trial name
- NCT03367780
- Testing
- PSMA PET/CT-scan
- Where
- 3 sites in Netherlands
- Volunteers
- 32 people
- Sponsor
- The Netherlands Cancer Institute